drugset / Trial / NCT04455126

Preservative-free Tafluprost Eye Drops in Newly Diagnosed Patients With Glaucoma

NCT04455126

Phase 2/3 Completed 30 enrolled Alexandria University
NaSingle-groupOpen-labelTreatment

Summary

Glaucoma encompasses a collective group of optic neuropathies characterized by progressive degeneration of retinal ganglion cells and their axons, resulting in cupping, a distinctive appearance of the optic disc, and a pattern of visual loss

Timeline

Start
2018-04-01
Primary completion
2018-12-30
Completion
2020-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tafluprost Other / unclassified Other

Indications